The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

Eyestem Research secures $10 million funding to advance innovative retinal therapies, aiming for global expansion and ...

A complex case of uveitis linked to syphilis highlights the need for thorough history-taking and multidisciplinary management ...